Skip to main content
  • Contact Us
  • Vantage logo Sign Up
  • Subscriber Sign In
Evaluate Logo

navigation

  • COVID-19
    • COVID-19 Update
    • Evaluate Vantage COVID-19 Report
    • COVID-19 Stories from Evaluate Vantage
    • Evaluate’s Business Continuity Plan
  • What We Do
    • Commercial Intelligence
    • Products
      • Evaluate Pharma
      • Evaluate Omnium
      • Evaluate Epi
      • Japan Drug Forecasts
      • Europe Drug Forecasts
    • Evaluate Custom Solutions
    • Evaluate Vantage
      • News
      • Analysis
      • Policy & Pricing
      • Data Insights
      • Events
      • Medtech
      • Therapy Areas
      • Editorial Team
      • About Evaluate Vantage
    • Evaluate for Biotech
  • How We Can Help You
    • Pharma and Biotech
    • Medtech
    • Financial Services
    • Management Consultancies
    • Service Providers
    • Customer Testimonials
  • Thought Leadership
  • About Us
    • Press Releases
    • Media Coverage
    • Executive Team
    • Vision & History
    • Careers
      • Current Vacancies
  • Contact Us
  • Sign Up for Evaluate Vantage
  • Subscriber Sign In

 

Vantage logo

Vantage

  • Covid-19
    • Covid-19 Coverage
    • Evaluate Vantage COVID-19 Report
  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Data Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas
  • About
    • Editorial team

Monoclonal Antibody

Thumbnail
February 25, 2021

Glaxo fails to win an Oscar

There might be a use for Glaxo’s anti-Covid-19 antibody otilimab in old patients, but repeating Actemra’s trick will not be easy.

Thumbnail
February 15, 2021

Regeneron’s Evkeeza leads a new class of lipid lowerers

Article image
Vantage logo
February 12, 2021

Asco-GU – confirmatory Padcev trial throws a curveball

Subgroup analysis of a confirmatory US study in bladder cancer suggests no benefit in female patients.

Article image
Vantage logo
February 10, 2021

Keytruda’s early breast cancer use likely requires patience

Article image
Vantage logo
January 30, 2021

World Lung 2020 – Yervoy’s front-line impotence laid bare

Full data show just how big a bust Keynote-598 is, though Bristol is unlikely to abandon hope.

Article image
Vantage logo
January 28, 2021

Pandemic mutations prompt antibody collaborations

A trial testing a combination of Lilly and Vir antibodies is the latest attempt by developers to stay ahead of the virus that causes Covid-19.

Article image
Vantage logo
January 27, 2021

Vir becomes a biotech bubble poster child

The company surges 74% though its hints of clinical activity concern just six hep B patients and could include those on placebo.

Article image
Vantage logo
January 26, 2021

Lilly’s Covid-19 combo catches fire

With no deaths in the treatment arm, Blaze-1 could allow emergency authorisation of the doublet antibody therapy.

Article image
Vantage logo
January 26, 2021

A second prophylaxis win for Covid-19 antibodies

Like Lilly, Regeneron reckons its antibodies can be used to prevent Covid-19 infection. Now comes the hard part.

Article image
Vantage logo
January 21, 2021

Lilly Blazes a trail in Covid-19 prevention

Article image
Vantage logo
January 21, 2021

Merck KGaA’s dual immuno-oncology weapon misfires

Bintrafusp alfa’s most important study, head to head against Keytruda in front-line lung cancer, is scrapped.

  • Load More
We use cookies on this website. By using this site, you agree that we may store and access cookies on your device. Find out more.
Vantage logo
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up

Latest Reports

February 11, 2021

Evaluate Vantage Pharma, Biotech & Medtech 2020 in Review

December 10, 2020

Evaluate Vantage 2021 Preview

View more...

Editor's Picks

Vantage logo
February 10, 2021

2020 wins top of the froths for biotech stocks

Vantage logo
October 04, 2018

Biotech flotations remain in high demand

Vantage logo
February 04, 2021

Glaxo’s growth problem

Vantage logo
January 27, 2021

Go or no go? Oncology decisions ahead for the FDA

Vantage logo
February 05, 2021

Pfizer reveals its PD-1 secret

Open modal

Evaluate HQ
44-(0)20-7377-0800

Evaluate Americas
+1-617-573-9450

Evaluate APAC
+81-(0)80-1164-4754

Footer menu

  • Terms and Conditions
  • Privacy Policies
  • Cookie Policy

© Copyright 2021 Evaluate Ltd.